Consensus EPS · Q1 2026
$6.96
Consensus revenue · Q1 2026
$71.6B
Analysts
4
Expected report
May 6, 2026
Analyst consensus (locked)
Analyst consensus
Based on estimates from 4 analysts.
| Metric | Low | Consensus | High |
|---|---|---|---|
| Revenue | $67.5B | $71.6B | $95.5B |
| EPS | $5.31 | $6.96 | $10.09 |
| EBITDA | $38B | $40.7B | $44.3B |
| EBIT | $31.2B | $33.4B | $36.3B |
| Net income | $23.8B | $25.5B | $27.6B |
Historical beat/miss
Actual reported results vs. analyst consensus at the time. Positive = beat, negative = miss.
| Period | Rev. actual | Rev. est. | Rev. surprise | EPS actual | EPS est. | EPS surprise |
|---|---|---|---|---|---|---|
| Q4 2025 | $12.5B | $77.1B | −83.8% | $1.02 | $5.87 | −82.6% |
Estimate revisions
How analyst consensus estimates have changed over the past 90 days.
Revision trends appear once we have collected at least two daily snapshots for this period.
Community vs analysts
See how the TickerLeague crowd's forecast stacks up against Wall Street.
Be the first to predict
No community consensus for Novo Nordisk (NVO) Q1 2026 yet. Make a prediction to start the crowd forecast.
Analyst price target
Based on price targets from 0 analysts.
| Low | Consensus | Median | High | Current | Upside |
|---|---|---|---|---|---|
| $45.00 | $49.50 | $49.50 | $54.00 | $42.96 | +15.2% |
Upside calculated vs most recent trading price of $42.96.
Analyst ratings
Consensus: Buy — based on 39 analyst ratings.
12-month trend
Recent analyst actions
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 2, 2026 | Goldman Sachs | downgrade | Buy | Neutral |
| Feb 24, 2026 | JP Morgan | downgrade | Overweight | Neutral |
| Dec 8, 2025 | Argus Research | downgrade | Buy | Hold |
| Nov 28, 2025 | Goldman Sachs | maintain | Buy | Buy |
| Nov 25, 2025 | BMO Capital | maintain | Market Perform | Market Perform |
| Nov 24, 2025 | HSBC | downgrade | Buy | Hold |
| Oct 14, 2025 | BMO Capital | maintain | Market Perform | Market Perform |
| Oct 2, 2025 | HSBC | upgrade | Hold | Buy |
| Sep 29, 2025 | Morgan Stanley | downgrade | Equal Weight | Underweight |
| Sep 17, 2025 | Berenberg | upgrade | Hold | Buy |
Novo Nordisk (NVO) Key Financials
Charts, filings, and peer comparison for every metric
Frequently asked questions
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation